Background: Metastatic breast cancer (MBC) is a highly heterogeneous disease with great differences in outcome to both chemo-and endocrine therapy. Better insight into the mechanisms underlying resistance is essential to better predict outcome to therapy and to obtain a more tailored treatment approach. We have previously described that increased mRNA expression levels of Enhancer of Zeste homolog (EZH2) are associated with worse outcome to tamoxifen therapy in MBC. Here, we explored whether this is also the case for EZH2 protein expression.
introduction
For already >30 years, both primary and metastatic breast cancer (MBC) patients with estrogen receptor (ER)-expressing tumors greatly benefit from endocrine therapies such as tamoxifen. However, outcome to tamoxifen differs considerably between MBC patients with ∼30% not benefitting at all while virtually all patients who initially benefit eventually develop progressive disease due to acquired resistance. Consequently, there is a high need to get more insight into the factors causing resistance to tamoxifen in order to develop methods to overcome resistance and to identify biomarkers to obtain a more personalized treatment approach. Numerous factors have already been revealed to account for resistance to endocrine therapy including loss of ER expression [1] [2] [3] , overexpression of the HER2 receptor [4] , and hyperactivation of the phosphatidylinositol 3-kinase (PI3 K) pathway [5] , and have subsequently led to the development of new targeted therapies [6, 7] . Additionally, we have previously identified overexpression of EZH2 as a potential factor involved in therapy resistance [8, 9] . EZH2, being a histone methyltransferase that mediates di-and trimethylation of lysine residue 27 on histone 3 (H3K27), comprises the catalytic subunit of the Polycomb Repressor Complex 2 (PCR2) and belongs to the Polycomb group (PcG) proteins. These proteins mainly act as transcriptional repressors of multiple genes involved in embryonic development, cell differentiation, and carcinogenesis [10] [11] [12] . EZH2 has been found to play a pivotal role in the tumorigenic process since its expression has been shown to be upregulated in several malignancies including prostate cancer [13] , lymphomas [14, 15] , urogenital tract tumors [16] [17] [18] , and breast cancer [19] . Concerning the latter, increased expression of EZH2 protein has been associated with a high histological grade and worse survival suggesting its promising role as a prognostic biomarker for aggressive breast cancer [18] [19] [20] [21] . Additionally, EZH2 has been proposed as a therapeutic target due to its association with tumor aggressiveness in several tumor types [18] [19] [20] [21] [22] [23] . Recently, small-molecule inhibitors of EZH2 histone methyltransferase activity have showed to decrease global H3K27me3 levels resulting in reactivation of silenced target genes and inhibition of proliferation, particularly in lymphomas with EZH2-activating mutations [24] . In breast cancer, we have previously shown that low expression of EZH2 mRNA was associated with a favorable response to tamoxifen treatment in MBC patients as well as, using in vitro silencing techniques, in a preclinical setting, which suggests EZH2 as a new potential therapeutic target [9] . However, this study was carried out on mRNA expression levels of EZH2 while the predictive value of EZH2 on protein expression level has not yet been studied. In the current study, we explored the association between protein expression of EZH2 and PFS in tamoxifentreated MBC patients.
patients and methods

ethics statement
This retrospective study, in which coded tumor tissues were used, has been approved by the medical ethics committee of the Erasmus MC Rotterdam, The Netherlands (MEC 02.953). Informed consent was not required. The study was carried out in accordance with the Code of Conduct of the Federation of Medical Scientific Societies in The Netherlands (http://www. fmwv.nl) and has been reported, wherever possible, following the REMARK guidelines [25] .
patients and tumor tissues
Patients with primary operable ER-positive breast cancer between 1985 and 1998 and from whom a formalin-fixed, paraffin-embedded primary breast tumor tissue specimen was available were included in the study provided that they subsequently developed MBC treated with first-line tamoxifen and detailed clinical follow-up data were available. In order to be included for final analysis, tumor specimens needed to have sufficient tumor material to obtain three independent cores. Central pathology review of the primary tumor was carried out by a breast pathologist (CvD), which included histologic subtype according to the World Health Organization (WHO) and histologic grade defined according to the modified Bloom-Richardson score based on the percentage of tubule formation, nuclear pleomorphism, and mitotic activity [26] . After applying the inclusion criteria of having three independent tumor cores per patient, tumor core biopsies on a breast tissue microarray (TMA) (for details see supplementary materials and methods, available at Annals of Oncology online) for 250 of the 316 available patients were selected for further analyses. Of these 250 patients, 106 (42%) underwent breast conserving surgery and 144 modified mastectomy (58%). Median follow-up time was 98 months (range 9-222 months). One hundred fifty-three patients (61%) did not receive adjuvant systemic therapy, while 77 (31%) were treated with adjuvant chemotherapy and 20 (8%) had metastatic disease upon diagnosis. None of the patients received adjuvant hormonal therapy. Response to first-line tamoxifen treatment, as assessed by RECIST criteria (version 1.1; http://www.eortc.be/recist/), was observed in 156 patients (62%) of whom 7 had complete response (CR; 3%), 42 a partial response (PR; 17%), and 107 (43%) stable disease for >6 months. Ninety-four patients (38%) did not have clinical benefit.
PFS was used as end point with PFS defined as the time elapsed between start of tamoxifen therapy and the first detection of disease progression or death, whatever came first during treatment. Detailed clinicopathological information for these 250 patients is provided in Supplementary Table S1 , available at Annals of Oncology online.
immunohistochemical evaluation EZH2 staining was interpreted and recorded independently by two experienced observers (EAR and AMT) in a blinded manner. Expression was assessed using a combination of both intensity (0 no staining, 1 weak, 2 moderate, and 3 strong) and proportion of cells stained for EZH2 (1 ≤10%, 2 11%-50%, and 3 ≥50%) according to the method described previously by Bachmann et al. [18] . Scores were multiplied to a maximum of 9 and a cutoff of >3 was considered as EZH2 positive.
data analysis and statistics
Statistical analyses were done with the STATA statistical package, release 12.0 (STATA Corp., College Station, TX). The relationship of EZH2 expression with patient and tumor characteristics was investigated using Pearson's χ 2 test or Fisher's exact when expected numbers were too small. The Cox proportional hazards model was used to compute the hazard ratio (HR) with the 95% CI in the analysis of PFS. In multivariate analysis, logistic and Cox regression analysis were used to determine whether the intensity and quantity of EZH2 expression had predictive value and were independent when added to the base model of traditional factors. Survival curves were generated using the Kaplan-Meier method and a log-rank test was used to test for differences between survival curves. When more than 2 curves were compared a log-rank test for trend was used for ordered categories. All P values were two-sided and P < 0.05 was considered statistically significant. Table S2 , available at Annals of Oncology online, Figure 1 ).
association between EZH2 protein expression with clinicopathological characteristics receptor (PgR) status, dominant site of relapse (DSR), and disease-free interval (Supplementary Table S1 , available at Annals of Oncology online). A significant positive association was observed with age, the amount of lymph nodes involved at initial diagnosis, histologic grade, and HER2/neu status.
association of EZH2 protein expression with PFS
In univariate analysis, the presence of EZH2 protein expression was significantly associated with PFS (HR 1.51, 95% CI 1.17-1.97, P = 0.002) ( Table 1 and Figure 2A ). When considering intensity and quantity separately, intensity showed no relation with PFS ( Figure 2B ). Quantity was associated with PFS with tumors with >50% EZH2-positive cells (N = 31) having the poorest PFS (HR 2.15, 95% CI 1.42-3.27, P < 0.001) ( Table 1 and Figure 2C ). In multivariate analysis, when corrected for traditional predictive factors including age, menopausal status, adjuvant therapy, DSR, DFS, PgR, and HER2/neu status, tumors with EZH2 protein expression were significantly associated with poor PFS (HR 1.41, 95% CI 1.06-1.88, P = 0.017) compared with tumors that scored negative for EZH2 protein expression. The overall survival data showed a HR of 1.31 with 95% CI 0.99-1.73, P = 0.055.
discussion
In the present study, we demonstrate the association between high levels of protein expression of EZH2 and poor outcome to endocrine therapy in ER-positive MBC patients treated with first-line tamoxifen. To our best knowledge, this is the first study that shows a relationship between EZH2 protein expression and outcome to tamoxifen therapy in MBC. These results are concordant with our previous study showing a similar association based on EZH2 mRNA levels [9] . There, we also found an association between high EZH2 mRNA expression and lower clinical benefit. In this study, we could establish similar results on protein level with an association between EZH2 protein expression and a worse response rate, defined as CR and PR after initiation of therapy (odds ratio 0.17, 95% CI 0.10-0.29, P < 0.001; data not shown). Of the 250 patients in this study, we had EZH2 mRNA data available of 66 patients (26%). In this small subgroup, we observed a significant positive correlation between presence of EZH2 protein and EZH2 mRNA (P = 0.04) (Supplementary Figure S1 , available at Annals of Oncology online). EZH2 has previously been suggested to bear prognostic value in several types of cancer. By using the same technique of TMAs, Alford et al. reported higher EZH2 expression in invasive breast carcinomas that relapsed after primary diagnosis compared with those that did not, regardless of received systemic adjuvant therapy [27] . As expected in our study of ER-positive tumors, most of the tumors were classified as moderately differentiated. The poorly differentiated tumors were more often EZH2 positive compared with the well and moderately differentiated. In accordance with our findings, an association between high EZH2 expression and high histologic grade has been demonstrated multiple times despite the use of different methods to classify the differentiation of tumors [18, 20, 21] .
Importantly, the assessment of scoring protein expression is semiquantitative and several methods exist. One of the most widely used methods to evaluate nuclear immunostaining is the Allred score in which quantity and intensity are also involved but quantity is composed of six categories [28] . This complex method is convenient to use for commonly expressed factors as ER, EGFR, and PgR [29] [30] [31] , but it is difficult to divide less frequently expressed factors such as EZH2 into the six different quantity categories. Since there is no golden standard for scoring EZH2, we used the method of Bachmann et al. [18] in which the product of intensity and quantity is used and a cutoff value of >3 to quantify tumors as EZH2 positive. However, other studies on EZH2 protein expression in breast cancer used different criteria. Kleer et al. [19] and Alford et al. [27] [32] . This method has been used to classify the expression of the seven in absentia homolog 2 (SIAH2) protein in breast tumors and uses a sum of intensity and quantity with a cutoff value of >2 to quantify tumors as SIAH2 positive. Application of this method to EZH2 scoring resulted in a similar association between EZH2 protein expression and PFS (Supplementary Figure S2C and Tables S3C and S4, available at Annals of Oncology online). Thus, the relation seems to be independent of the method of scoring, as long as the amount proportion of stained cells is included since intensity by itself did not associate with PFS, whereas quantity did according to different methods. Considering downstream effects of EZH2, we have previously shown that silencing of EZH2 in the ER-positive cell line MCF7 leads to a higher expression of ER and increased sensitivity to antiestrogen treatment [9] . The present study confirms this association between EZH2 and sensitivity to tamoxifen by demonstrating the association between high EZH2 protein expression and poor outcome to first-line tamoxifen treatment in MBC patients. Therefore, adding EZH2 inhibition to antiestrogen therapies is an approach worthwhile to explore in MBC and EZH2 expression might be the biomarker to select patients who benefit most.
Recently, several EZH2 inhibitors have been developed and preclinically tested in multiple types of cell lines and xenografts [33, 34] . Both EPZ-6438 (E7438) and GSK126 as selective small-molecule inhibitors of histone methyltransferase activity have shown promising results in both small-cell lung cancer (SCLC) cell lines and malignant rhabdoid tumors xenografts. The most convincing preclinical results have been obtained in lymphomas, which often bear EZH2-activating mutations [24] . This has led to the recent start of a phase I/II trial in patients with EZH2-mutated B-cell lymphomas (www.clinicaltrials.gov, NCT01897571). EZH2 mutations have not yet been described in other types of tumors.
In conclusion, we demonstrate that high EZH2 protein levels are associated with unfavorable outcome to tamoxifen treatment in MBC patients. We explored multiple methods for scoring EZH2 protein levels leading to a preference for the use of quantity or the sum or product of intensity and quantity over intensity alone due to their significant association with PFS. The association of EZH2 expression, both at the mRNA and the protein level, with outcome to tamoxifen in MBC and the previous finding that downregulation of EZH2 increases ER expression and subsequently, sensitivity to anti-estrogen treatment in preclinical models renders EZH2 an attractive target to explore in combination with anti-estrogen treatment in ER-positive breast cancer. Furthermore, its assessment could be used to categorize patients according to their likelihood to benefit from tamoxifen and if confirmed, could allow a better selection of patients for tamoxifen and a more personalized treatment approach. 
